Shopping Cart
Remove All
Your shopping cart is currently empty
VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated
(Synonyms: VEGFR2, VEGFR, kinase insert domain receptor, Flk-1, FLK1, CD309) Copy Product InfoSynonyms: VEGFR2, VEGFR, kinase insert domain receptor, Flk-1, FLK1, CD309
Catalog No. TMPY-04940 Copy Product Info
VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.6 kDa and the accession number is P35968-1.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 5 µg | $112 | 7-10 days | 7-10 days | |
| 10 µg | $183 | 7-10 days | 7-10 days | |
| 20 µg | $306 | 7-10 days | 7-10 days | |
| 50 µg | $492 | 7-10 days | 7-10 days | |
| 100 µg | $842 | 7-10 days | 7-10 days |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Bioactivity | 1.Measured by its ability to bind human VEGF165 in functional ELISA.
2. Immobilized human VEGF165 at 10μg/mL (100μL/well) can bind biotinylated human KDR, the EC50 of biotinylated human KDR is 50-160ng/mL. |
| Description | VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 84.6 kDa and the accession number is P35968-1. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-His |
| Accession Number | P35968-1 |
| Construction | A DNA sequence encoding the extracellular domain of human VEGFR2 (NP_002244.1) (Met 1-Glu 764) was fused with a polyhistidine tag at the C-terminus. Predicted N terminal: Ala 20 |
| Protein Purity | > 95% as determined by SDS-PAGE. |
| Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
| Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
| Synonyms | VEGFR2, VEGFR, kinase insert domain receptor, Flk-1, FLK1, CD309 |
| Research Background | VEGFR2 also called KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling are critical to endothelial cell survival, maintenance of the vasculature and alveolar structure, and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Molecular Weight | 84.6 kDa (predicted) |
| Shipping | In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice. |
| Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Recombinant Proteins
Preview
Related Tags: VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated chemical structure | VEGFR2/KDR Protein, Human, Recombinant (His), Biotinylated molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.